Vaxcyte, Inc. (PCVX) · Oct 9, 2026 · Share issuance

Vaxcyte financing closes at $1.1B ahead of VAX-31 data

$1.1B financing — $544.3M equity proceeds + $558.7M debt proceeds

Vaxcyte’s financing closes with $544.3M equity and $558.7M convertible-debt proceeds, funding late-stage VAX-31 work but adding dilution and debt.

Vaxcyte is a clinical-stage vaccine company moving VAX-31 through its adult Phase 3 program while building manufacturing capacity and preparing for potential commercialization; OPUS-1 topline data is expected by the end of October 2026.

The key change is funding, not new clinical evidence. The concurrent offerings generated approximately $1.103 billion of net proceeds: $544.3 million from equity and $558.7 million from convertible notes. This materially strengthens the balance sheet for Phase 3 execution, manufacturing scale-up and commercial readiness, but the equity leg increases the share base and the debt leg creates a future repayment or conversion obligation.

Financing componentTerms / proceeds
Equity offering8,584,375 shares plus 400,000 pre-funded warrants at $64.00 per share or warrant (Item 8.01 — Other Events)
Convertible notes$575.0 million principal, 1.50% due October 2032; initial conversion price approximately $89.60 per share (Item 1.01 — Material Definitive Agreement)
Net equity proceeds$544.3 million (Item 8.01 — Other Events)
Net debt proceeds$558.7 million (Item 8.01 — Other Events)
Total net proceedsApproximately $1.103 billion

The financing is strategically well timed but not a surprise. Vaxcyte announced the offerings on October 6, exercised both overallotment options on October 7, and closed them on October 9; the filing mainly confirms completion and final proceeds rather than introducing an unexpected capital plan. The 1.50% coupon is relatively low-cost funding, while the roughly $89.60 conversion price sits above the $64.00 equity-offering price, limiting immediate conversion pressure but leaving potential future dilution if the company succeeds.

The event buys execution time before the next value-defining test. Vaxcyte already had substantial liquidity, including $2.5 billion of cash, cash equivalents and investments at June 30, 2026, so this is less a rescue financing than an effort to pre-fund the expensive transition from late-stage trials toward manufacturing and launch preparation. The business signal is therefore constructive for execution capacity, but the financing itself does not reduce the clinical risk around VAX-31.

Bottom line: Vaxcyte has locked in more than $1.1 billion to advance VAX-31 and its commercial buildout, but the filing confirms a previously telegraphed raise rather than delivering new product evidence. It strengthens funding visibility while adding dilution and debt ahead of the imminent OPUS-1 readout.

What to watch next

OPUS-1 topline data, expected by end of October 2026

Original filing on SEC EDGAR

More Vaxcyte, Inc. news

Vaxcyte financing closes at $1.1B ahead of VAX-31 data | PCVX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.